Objective Anlotinib, an oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor,
has confirmed antitumor activity in lung cancer in both in vitro and in vivo assays, and has …

Abstract Lessons Learned The combination of anlotinib and S-1 exhibited good antitumor
activity in third-or later-line treatment for stage IV non-small cell lung cancer (NSCLC) …

Methods This study is a non-interventional, prospective, multi-center observational study of
real world cases and all registered data are collected from real clinical practice cases. Adult …

Importance Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis
and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free …

e21106 Background: Anlotinib is an oral novel receptor tyrosine kinases (RTKs) inhibitor
targeting multiple RTKs including VEGFR, PDGFR, FGFR, and c-kit. Due to its high efficacy …

There is no standard treatment strategy for the third-line and above treatment of advanced
nonsmall cell lung cancer (NSCLC). This study aimed to investigate the effects of anlotinib in …

e21115 Background: At present, for stage IV non-small-cell lung cancer (NSCLC), after the
failure of second-line treatment, the effective rate of third-line treatment is not very well. We …

Objective To assess the efficacy and toxicity of anlotinib for the treatment of refractory
advanced non-small-cell lung cancer (NSCLC). Methods We systematically searched …

Purpose The ALTER0303 trial showed that anlotinib, a novel antiangiogenic tyrosine kinase
inhibitor, administered as third-line or further treatment prolonged progression-free survival …

Aim: The aim of this randomised, double-blind, placebo-controlled, anlotinb study was to
investigate its efficacy and safety in patients with refractory non-small-cell lung cancer …